Laws · federal-policy

Companies Warn New DEA Policy Imperils Medical Marijuana Markets

Law360 reports that cannabis companies say a new DEA policy threatens state medical marijuana markets, though the underlying policy text was not available to CannIntel.

By Niko Adamou, Hemp & THCA ReporterPublished November 19, 20263 min read
Close-up of the Department of Agriculture building's architectural facade, showcasing intricate columns and windows.

Close-up of the Department of Agriculture building's architectural facade, showcasing intricate columns and windows.

Cannabis companies say a new Drug Enforcement Administration policy imperils state medical marijuana markets, Law360 reported November 19. The report's details were limited in the signal reviewed. The stakes are federal enforcement exposure for operators licensed under state medical programs.

What the report says

Law360 reported on November 19, 2026, that companies say a new DEA policy puts medical marijuana markets at risk. That headline is the extent of what the signal supplies.

CannIntel's review didn't include the article text, the policy's title, its effective date or the names of the companies raising concerns. We aren't going to guess at them. Anything beyond the Law360 headline is unconfirmed.

That gap matters. A DEA policy can mean a rule, a guidance memo, an enforcement priority or a registration change, and each carries a different legal weight.

Why the details decide everything

The legal force of a DEA action determines whether it is a binding threat or a signal of enforcement posture. A final rule under the Controlled Substances Act binds. A guidance document or internal memo doesn't, though it can still chill lending, banking and licensing decisions.

Operators in state medical programs have long relied on informal federal restraint rather than statutory protection, which is why any shift in DEA posture lands hardest on them.

State medical markets sit in a familiar bind. They operate lawfully under state statute while marijuana stays federally controlled. The protections they lean on are thin, and they're renewable only through appropriations language. For the broader policy arc, see the CannIntel topic hub on DEA medical marijuana policy.

Hemp-derived products are a separate fight. The delta-9 versus total-THC question, including how THCA converts to delta-9 THC through decarboxylation, is governed by the Agricultural Improvement Act's hemp definition, not by the marijuana scheduling track. Nothing in the signal ties this policy to hemp. We won't imply it does.

What operators should watch

The first confirmable facts will come from the policy document itself and from any Federal Register notice. Operators and counsel should look for the issuing office, the statutory authority cited, any comment period, and an effective date.

Regulators in California, Florida and other large medical markets typically respond within days of a federal shift, usually with bulletins to licensees. Those bulletins often reveal the practical read faster than the federal text does.

It's unsettled. Expect enforcement to vary by region and by U.S. Attorney's office, and expect companies' public warnings to run ahead of any actual enforcement action. CannIntel will update this story once the policy text and named sources are verified.

Full context

For complete background, history, and our ongoing coverage of this story:

Open the CannIntel topic hub →

Frequently asked questions

What did Law360 report about the DEA?

Law360 reported on November 19, 2026, that companies say a new DEA policy imperils medical marijuana markets. The policy's specifics and the companies involved were not available in the signal CannIntel reviewed, so those details remain unverified.

Does this affect hemp or THCA products?

Nothing in the available signal links the policy to hemp or THCA. Hemp is governed by the Agricultural Improvement Act's definition, including the delta-9 THC limit, which is a separate legal track from marijuana scheduling.

Is a DEA policy the same as a DEA rule?

No. A final rule under the Controlled Substances Act is binding. Guidance or an internal enforcement memo is not binding but can still affect banking, lending and licensing behavior across state markets.

Where can operators find the policy text?

Operators should check the DEA's website and the Federal Register for any notice, and watch for bulletins from their state cannabis regulator, which often interpret federal shifts quickly.

Sources

DEAmedical marijuanafederal cannabis policyControlled Substances Actstate medical programscannabis enforcement
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.

Related from Laws

More from the newsroom